Stephens Inc. AR increased its holdings in shares of Cigna Corp (NYSE:CI) by 101.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,264 shares of the health services provider’s stock after purchasing an additional 2,146 shares during the quarter. Stephens Inc. AR’s holdings in Cigna were worth $686,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in the company. Bank of New York Mellon Corp lifted its holdings in Cigna by 56.2% in the fourth quarter. Bank of New York Mellon Corp now owns 3,304,407 shares of the health services provider’s stock valued at $627,573,000 after acquiring an additional 1,189,307 shares during the period. Edmp Inc. increased its position in Cigna by 5.9% in the first quarter. Edmp Inc. now owns 3,942 shares of the health services provider’s stock worth $634,000 after buying an additional 219 shares in the last quarter. IBM Retirement Fund increased its position in Cigna by 40.1% in the fourth quarter. IBM Retirement Fund now owns 6,217 shares of the health services provider’s stock worth $1,181,000 after buying an additional 1,778 shares in the last quarter. Raymond James Trust N.A. increased its position in Cigna by 1.5% in the first quarter. Raymond James Trust N.A. now owns 15,552 shares of the health services provider’s stock worth $2,501,000 after buying an additional 224 shares in the last quarter. Finally, Gotham Asset Management LLC increased its position in Cigna by 281.4% in the fourth quarter. Gotham Asset Management LLC now owns 221,113 shares of the health services provider’s stock worth $41,994,000 after buying an additional 163,135 shares in the last quarter. 88.61% of the stock is currently owned by hedge funds and other institutional investors.

In other Cigna news, insider Brian C. Evanko purchased 2,000 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The stock was purchased at an average cost of $163.40 per share, with a total value of $326,800.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director William D. Zollars sold 272 shares of the firm’s stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $168.43, for a total value of $45,812.96. The disclosure for this sale can be found here. 0.80% of the stock is owned by company insiders.

Shares of NYSE:CI traded up $2.12 during trading on Tuesday, hitting $155.79. The company had a trading volume of 634,541 shares, compared to its average volume of 2,893,006. The firm has a market capitalization of $58.42 billion, a price-to-earnings ratio of 10.96, a PEG ratio of 0.76 and a beta of 0.69. Cigna Corp has a one year low of $141.95 and a one year high of $226.60. The company has a debt-to-equity ratio of 0.89, a current ratio of 0.70 and a quick ratio of 0.70.

Cigna (NYSE:CI) last posted its quarterly earnings data on Thursday, May 2nd. The health services provider reported $3.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.74 by $0.16. The business had revenue of $33.43 billion during the quarter, compared to analyst estimates of $32.79 billion. Cigna had a return on equity of 14.23% and a net margin of 4.11%. The company’s revenue for the quarter was up 192.9% on a year-over-year basis. During the same period last year, the company earned $4.11 EPS. As a group, analysts expect that Cigna Corp will post 16.54 earnings per share for the current fiscal year.

CI has been the subject of a number of analyst reports. Goldman Sachs Group restated a “buy” rating on shares of Cigna in a research report on Saturday, February 2nd. Morgan Stanley cut their target price on Cigna from $304.00 to $299.00 and set an “overweight” rating for the company in a research report on Tuesday, February 5th. Zacks Investment Research cut Cigna from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 20th. ValuEngine cut Cigna from a “hold” rating to a “sell” rating in a research report on Thursday, February 28th. Finally, Barclays cut their target price on Cigna from $220.00 to $207.00 and set an “overweight” rating for the company in a research report on Wednesday, April 17th. One research analyst has rated the stock with a sell rating, two have given a hold rating and fifteen have assigned a buy rating to the company’s stock. Cigna currently has a consensus rating of “Buy” and a consensus price target of $225.85.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.watchlistnews.com/cigna-corp-ci-shares-bought-by-stephens-inc-ar/3017803.html.

About Cigna

Cigna Corporation, a health service organization, provides insurance and related products and services in the United States and internationally. It operates through Integrated Medical, Health Services, International Markets, and Group Disability and Other segments. The Integrated Medical segment offers medical, pharmacy, dental, behavioral health and vision, health advocacy programs, and other products and services to insured and self-insured clients; Medicare Advantage, Medicare Supplement, and Medicare Part D plans to Medicare-eligible beneficiaries, as well as Medicaid plans; and health insurance coverage to individual customers on and off the public exchanges.

Further Reading: What is Depreciation?

Want to see what other hedge funds are holding CI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cigna Corp (NYSE:CI).

Institutional Ownership by Quarter for Cigna (NYSE:CI)

Receive News & Ratings for Cigna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna and related companies with MarketBeat.com's FREE daily email newsletter.